IP Library Granted Patent US 10,556,877
Granted Patent B2
US 10,556,877 · App. 15/571,112 · Granted Feb 11, 2020

Process for preparation of dapagliflozin

Inventors: Shekhar Bhaskar Bhirud (Mumbai, IN); Kumar Hari Bhushan (Gurgaon, IN); Raghu Ram Suraparaju (Hyderabad, IN); Nandkumar Gaikwad (Navi Mumbai, IN); Sharad Gore (Thane, IN); Rajendra Jagdhane (Pune, IN); Mandar Kulkarni (Pune, IN)
Assignee: Glenmark Life Sciences Limited
C07D309/10A61K31/70B01D9/0054C07B51/00C07B63/04C07C31/207C07H7/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,556,877
App. No.
15/571,112
Granted
Feb 11, 2020
Kind
B2
Abstract

The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.

Claims (18)

1. A process for the preparation of dapagliflozin in amorphous form, the process comprising:

(a) reducing a compound of formula II to a compound of formula III in the presence of a Lewis acid;

wherein the compound of formula II is prepared by reacting 5-bromo-2-chlorobenzoyl chloride with ethoxybenzene;

(b) silylating a compound of formula IV with hexamethyldisilazane to form a compound of formula V;

(c) reacting the compound of formula III with the compound of formula V in the presence of a strong base followed by treatment with an acid in the presence of an alcohol to prepare a compound of formula VII, wherein R is an alkyl group selected from C 1-5 alkyl;

(d) converting the compound of formula VII to dapagliflozin;

(e) acetylating dapagliflozin to give D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, 2,3,4,6-tetraacetate, (1S)-, a compound of formula VIII;

(f) purifying the compound of formula VIII by a series of crystallizing steps to obtain the compound of formula VIII with a purity of ≥99.6%, wherein the series of crystallizing steps comprises:

(1) crystallizing the compound of formula VIII with methanol,

(2) crystallizing the product of step (f)(1) with diisopropyl ether, and

(3) crystallizing the product of step (f)(2) with methanol;

(g) hydrolyzing the compound of formula VIII obtained in step (f) to give dapagliflozin;

(h) dissolving dapagliflozin of step (g) in isopropyl alcohol to form a solution; and

(i) recovering amorphous dapagliflozin from the solution of step (h), wherein the recovering comprises one of:

(1) removing the isopropyl alcohol from the solution obtained in step (h) comprising concentrating the solution of step (h) and degassing; or

(2) treating the solution of step (h) with cyclohexane,

wherein the amorphous dapagliflozin is obtained in a purity of ≥99.8% and wherein a level of impurity A and impurity B is less than 0.15%

2. The process of claim 1 , wherein step (c) comprises reacting the compound of formula III with the compound of formula V in the presence of a strong base to obtain a compound of formula VI; and reacting the compound of formula VI with an acid in the presence of an alcohol to obtain the compound of formula VII wherein R is an alkyl group selected from C 1-5 alkyl

Assignments (3)
CHANGE OF NAME Recorded Jan 7, 2025
From: GLENMARK LIFE SCIENCES LIMITED
To: ALIVUS LIFE SCIENCES LIMITED
Reel/Frame 069775/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 051100/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2017
From: BHUSHAN, KUMAR HARI; BHIRUD, SHEKHAR BHASKAR; SURAPARAJU, RAGHU RAM; GAIKWAD, NANDKUMAR; GORE, SHARAD; JAGDHANE, RAJENDRA; KULKARNI, MANDAR
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 044271/0968 →
Priority Claims (2)
IN 1790/MUM/2015 · May 5, 2015 · national
IN 201621002175 · Jan 20, 2016 · national
Continuity (1)
Related Publication 20180127391A1 · May 10, 2018